Clinical evidence has shown that anti–CTLA-4 therapy can enhance the activation of effector T cells (Maker et al., 2005), increase the ratio of effector T cells to Treg (Quezada et al., 2006; Curran et al., 2010; Ou et al., 2018), and promote the transport of activated T cells to tumor tissues (Quezada et al., 2006). The gene discussed is CTLA4; the disease is neoplasm.